Influence of Hormone Treatment in Radiation Therapy for Bladder Cancer
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
Bladder cancer is often treated with cystectomy or radiation therapy. Following radiation therapy patients will often have severe side effects from the treatment. Studies have suggested that simultanously treatment with androgen deprivation therapy during radiation therapy may be able to proctect stemcells in the bladder, thus improving tissue recovering post-radiation, which would result in improved bladder compliance following the treatment and ultimately result in fewer side effects and overall improved patient quality of life.
Eligibility
Participation Requirements
Sex: Male
Minimum Age: 18
View:
• T2-T4 bladder cancer
• radiation therapy
• able to fill out questionnaires
• signed informed consent
Locations
Other Locations
Denmark
Aarhus University Hospital
RECRUITING
Aarhus
Contact Information
Primary
Jørgen Jensen, Professor
bjerggaard@skejby.rm.dk
30915525
Time Frame
Start Date: 2020-02-19
Estimated Completion Date: 2025-10-31
Participants
Target number of participants: 60
Treatments
Degarelix
Patients undergoing radiation therapy for bladder cancer while also being treated with Degarelix (androgen deprivation therapy)
Control
Patients undergoing radiation therapy for bladder cancer with or without simultanous treatment with androgen deprivation therapy (not Degarelix)
Related Therapeutic Areas
Sponsors
Leads: Aarhus University Hospital